Regadenoson is a purine nucleoside analogue and a selective A2A adenosine receptor agonist used as a pharmacologic stress agent to induce coronary vasodilation during myocardial perfusion imaging for the… Read more

























Regadenoson is a purine nucleoside analogue and a selective A2A adenosine receptor agonist used as a pharmacologic stress agent to induce coronary vasodilation during myocardial perfusion imaging for the diagnosis of coronary artery disease. Laboratories require high-quality reference standards of the regadenoson API, as well as its related impurities, metabolites, and stable isotope-labelled compounds, to support rigorous analytical testing and quality control protocols. These materials are essential for reliable impurity profiling, method validation, and stability studies, ensuring adherence to regulatory standards throughout the pharmaceutical product lifecycle. By providing accurately characterized benchmarks for both pharmacopeial and non-pharmacopeial substances, these products enable laboratories to maintain data integrity and consistency during the assessment of drug identity, concentration, and performance in clinical and development settings.